Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.
Adamson
Catherine S
CS
Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Maryland, 21702-1201, USA. cadamson@ncifcrf.gov
Freed
Eric O
EO
D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D055808:Drug Discovery; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D011991:Receptors, Virus / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D011991:Receptors, Virus